It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
That's where CRISPR Therapeutics falls short. The company's approved product, Casgevy, is an ex vivo gene editing treatment.
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...
According to the approved data and research by England NHS in the UK, people of Middle Eastern, Mediterranean, south and ...
Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...
CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...
CASGEVYâ„¢ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback